The immunomodulatory effects of macrolides-A systematic review of the underlying mechanisms

Frontiers in Immunology

Volumn 9, Issue MAR, 2018, Pages

  Zimmermann, Petra ^a,b,c,d   Ziesenitz, Victoria C ^d   Curtis, Nigel ^a,b,c   Ritz, Nicole ^b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Azalides; Azithromycin; Clarithromycin; Erythromycin; Immunolides; Roxithromycin

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; EOSINOPHIL CATIONIC PROTEIN; ERYTHROMYCIN; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; ROXITHROMYCIN; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; BIBLIOGRAPHIC DATABASE; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; META ANALYSIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TH2 CELL;

EID: 85043526790     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00302     Document Type: Review

References (85)

1. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm (1992) 11(2):137-52
2. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, et al. Spectrum and mode of action of azithromycin (CP-62, 993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother (1987) 31(12):1939-47. doi:10.1128/AAC.31.12.1939
3. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am (2004) 18(3):621-49. doi:10.1016/j.idc.2004.04.010
4. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol (2003) 330(5):1005-14. doi:10.1016/S0022-2836(03)00662-4
5. Poliak MS. [Content of monomycin in bile and its effectiveness in inflammatory diseases and surgery of the biliary tract]. Antibiotiki (1963) 8:83-7
6. Parfenova EN, Ryviakova EV. [Use of erythromycin in non-specific inflammatory diseases of the Urogenital System]. Urol Mosc (1963) 28:29-31
7. Gluzman IS. [Erythromycin ointment therapy of inflammatory diseases of eyelid, conjunctiva and cornea. (Clinico-Experimental Studies)]. Oftalmol Zh (1964) 19:450-4
8. Plewig G, Schopf E. Anti-inflammatory effects of antimicrobial agents: an in vivo study. J Invest Dermatol (1975) 65(6):532-6. doi:10.1111/1523-1747.ep12610281
9. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med (1998) 157(6 Pt 1):1829-32. doi:10.1164/ajrccm.157.6.9710075
10. Hahn DL, Grasmick M, Hetzel S, Yale S, AZMATICS (AZithroMycin-Asthma Trial In Community Settings) Study Group. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med (2012) 25(4):442-59. doi:10.3122/jabfm.2012.04.110309
11. Koutsoubari I, Papaevangelou V, Konstantinou GN, Makrinioti H, Xepapadaki P, Kafetzis D, et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatr Allergy Immunol (2012) 23(4):385-90. doi:10.1111/j.1399-3038.2012.01280.x
12. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax (2006) 61(10):895-902. doi:10.1136/thx.2005.057950
13. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet (2012) 380(9842):660-7. doi:10.1016/S0140-6736(12)60953-2
14. Sadreddini S, Noshad H, Molaeefard M, Moloudi R, Ardalan MR, Ghojazadeh M. A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis. Int J Rheum Dis (2009) 12(1):44-51. doi:10.1111/j.1756-185X.2009.01379.x
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 339:b2700. doi:10.1136/bmj.b2700
16. Zhang L, Su Z, Zhang Z, Lin J, Li DQ, Pflugfelder SC. Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease. JAMA Ophthalmol (2015) 133(10):1117-23. doi:10.1001/jamaophthalmol.2015.2326
17. Ho W, Eubank T, Leblebicioglu B, Marsh C, Walters J. Azithromycin decreases crevicular fluid volume and mediator content. J Dent Res (2010) 89(8):831-5. doi:10.1177/0022034510368650
18. Gong Y, Lu J, Ding X, Yu Y. Effect of adjunctive roxithromycin therapy on interleukin-1beta, transforming growth factor-beta1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth. J Periodontal Res (2014) 49(4):448-57. doi:10.1111/jre.12123
19. Peric A, Vojvodic D, Matkovic-Jozin S. Effect of long-term, low-dose clarithromycin on T helper 2 cytokines, eosinophilic cationic protein and the 'regulated on activation, normal T cell expressed and secreted' chemokine in the nasal secretions of patients with nasal polyposis. J Laryngol Otol (2012) 126(5):495-502. doi:10.1017/S0022215112000485
20. Peric A, Vojvodic D, Baletic N, Peric A, Miljanovic O. Influence of allergy on the immunomodulatory and clinical effects of long-term low-dose macrolide treatment of nasal polyposis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2010) 154(4):327-33. doi:10.5507/bp.2010.049
21. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol (2000) 14(3):143-8. doi:10.2500/105065800782102717
22. MacLeod CM, Hamid QA, Cameron L, Tremblay C, Brisco W. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther (2001) 18(2):75-82. doi:10.1007/BF02852391
23. Cervin A, Wallwork B, Mackay-Sim A, Coman WB, Greiff L. Effects of long-term clarithromycin treatment on lavage-fluid markers of inflammation in chronic rhinosinusitis. Clin Physiol Funct Imaging (2009) 29(2):136-42. doi:10.1111/j.1475-097X.2008.00848.x
24. Wallwork B, Coman W, Mackay-Sim A, Cervin A. Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis. Laryngoscope (2004) 114(2):286-90. doi:10.1097/00005537-200402000-00019
25. Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med (1997) 182(2):115-24. doi:10.1620/tjem.182.115
26. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope (2006) 116(2):189-93. doi:10.1097/01.mlg.0000191560.53555.08
27. Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J (2013) 42(5):1412-5. doi:10.1183/09031936.00093913
28. He J, Zhu N, Chen X. Clinical impacts of azithromycin on lung function and cytokines for athmatic patients. JMS (2009) 36(6):719-22
29. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc (2007) 28(2):194-8. doi:10.2500/aap.2007.28.2958
30. Fonseca-Aten M, Okada PJ, Bowlware KL, Chavez-Bueno S, Mejias A, Rios AM, et al. Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol (2006) 97(4):457-63. doi:10.1016/S1081-1206(10)60935-0
31. Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol (2000) 84(6):594-8. doi:10.1016/S1081-1206(10)62409-X
32. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest (2002) 121(6):1782-8. doi:10.1378/chest.121.6.1782
33. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med (2008) 177(2):148-55. doi:10.1164/rccm.200707-1134OC
34. Wang Y, Zhang S, Qu Y. Effect of clarithromycin on non-eosinophilic refractory asthma. J Clin Pulm Med (2012) 17(11):1948-51
35. Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy (1999) 29(7):950-6. doi:10.1046/j.1365-2222.1999.00551.x
36. Kamoi H, Kurihara N, Fujiwara H, Hirata K, Takeda T. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma (1995) 32(3):191-7. doi:10.3109/02770909509089507
37. Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, Kolios G, Miltiades P, et al. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. Lung (2014) 192(6):849-55. doi:10.1007/s00408-014-9619-0
38. Yalçin E, Kiper N, Ozçelik U, Dogru D, Firat P, Sahin A, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther (2006) 31(1):49-55. doi:10.1111/j.1365-2710.2006.00708.x
39. Liu J, Zhong X, He Z, Wei L, Zheng X, Zhang J, et al. Effect of low-dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators Inflamm (2014) 2014:708608. doi:10.1155/2014/708608
40. Parnham MJ, Culic O, Erakovic V, Munic V, Popovic-Grle S, Barisic K, et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol (2005) 517(1-2):132-43. doi:10.1016/j.ejphar.2005.05.023
41. Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med (2004) 3(1):59-65. doi:10.2165/00151829-200403010-00007
42. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration (2010) 80(6):445-52. doi:10.1159/000321374
43. Park SJ, Lee YC, Rhee YK, Lee HB. The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis. Biochem Biophys Res Commun (2004) 324(1):114-7. doi:10.1016/j.bbrc.2004.09.018
44. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest (1994) 106(4):1116-23. doi:10.1378/chest.106.4.1116
45. Kadota J, Sakito O, Kohno S, Sawa H, Mukae H, Oda H, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis (1993) 147(1):153-9. doi:10.1164/ajrccm/147.1.153
46. Katsuki M. Neutrophil chemotactic activity in bronchoalveolar lavage fluid recovered from patients with diffuse panbronchiolitis. Kurume Med J (1996) 43(4):279-87. doi:10.2739/kurumemedj.43.279
47. Ichikawa Y, Ninomiya H, Koga H, Tanaka M, Kinoshita M, Tokunaga N, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis (1992) 146(1):196-203. doi:10.1164/ajrccm/146.1.196
48. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration (1996) 63(1):42-8. doi:10.1159/000196514
49. Umeki S. Anti-inflammatory action of erythromycin. Its inhibitory effect on neutrophil NADPH oxidase activity. Chest (1993) 104(4):1191-3
50. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest (2012) 142(5):1259-66. doi:10.1378/chest.12-0628
51. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet (2002) 360(9338):978-84. doi:10.1016/S0140-6736(02)11081-6
52. Dogru D, Dalgiç F, Kiper N, Ozçelik U, Yalçin E, Aslan AT, et al. Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. Turk J Pediatr (2009) 51(5):416-23
53. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm (2004) 13(2):111-7. doi:10.1080/09629350410001688495
54. Verleden SE, Vandooren J, Vos R, Willems S, Dupont LJ, Verleden GM, et al. Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients. Transpl Immunol (2011) 25(2-3):159-62. doi:10.1016/j.trim.2011.06.006
55. Berg HF, Maraha B, Scheffer GJ, Peeters MF, Kluytmans JA. Effect of clarithromycin on inflammatory markers in patients with atherosclerosis. Clin Diagn Lab Immunol (2003) 10(4):525-8
56. Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol (2002) 450(3):277-89. doi:10.1016/S0014-2999(02)02042-3
57. Criqui GI, Solomon C, Welch BS, Ferrando RE, Boushey HA, Balmes JR. Effects of azithromycin on ozone-induced airway neutrophilia and cytokine release. Eur Respir J (2000) 15(5):856-62. doi:10.1034/j.1399-3003.2000.15e08.x
58. Aubert JD, Juillerat-Jeanneret L, Fioroni P, Dayer P, Plan PA, Leuenberger P. Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers. Pulm Pharmacol Ther (1998) 11(4):263-9. doi:10.1006/pupt.1998.0123
59. Cervin A, Kalm O, Sandkull P, Lindberg S. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg (2002) 126(5):481-9. doi:10.1067/mhn.2002.124849
60. Tone A, Shikata K, Nakagawa K, Hashimoto M, Makino H. Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients. Clin Exp Nephrol (2011) 15(1):79-85. doi:10.1007/s10157-010-0357-1
61. Booth V, Young S, Cruchley A, Taichman NS, Paleolog E. Vascular endothelial growth factor in human periodontal disease. J Periodontal Res (1998) 33(8):491-9. doi:10.1111/j.1600-0765.1998.tb02349.x
62. Suzuki H, Ikeda K, Honma R, Gotoh S, Oshima T, Furukawa M, et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec (2000) 62(3):121-7. doi:10.1159/000027731
63. Akiyoshi H, Honda J, Nakahara S, Tokisawa S, Tokunaga N, Ichikawa Y, et al. [Mechanism of efficacy of erythromycin on diffuse panbronchiolitis-effect of erythromycin on cytokine mRNA expression in human whole blood model]. Kansenshogaku Zasshi (1994) 68(2):209-16. doi:10.11150/kansenshogakuzasshi1970.68.209
64. Bosnar M, Cužic S, Bošnjak B, Nujic K, Ergovic G, Marjanovic N, et al. Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia. Int Immunopharmacol (2011) 11(4):424-34. doi:10.1016/j.intimp.2010.12.010
65. Cheung PS, Si EC, Hosseini K. Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity. Ocul Immunol Inflamm (2010) 18(1):32-7. doi:10.3109/09273940903359725
66. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun (2006) 350(4):977-82. doi:10.1016/j.bbrc.2006.09.132
67. Yao GY, Ma YL, Zhang MQ, Gao ZC. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration (2013) 86(3):254-60. doi:10.1159/000350828
68. Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease. Respir Med (2013) 107(9):1385-92. doi:10.1016/j.rmed.2013.05.004
69. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev (2012) 11:Cd002203. doi:10.1002/14651858.CD002203.pub4
70. Welsh EJ, Evans DJ, Fowler SJ, Spencer S. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev (2015) 7:Cd010337. doi:10.1002/14651858.CD010337.pub2
71. Kew KM, Undela K, Kotortsi I, Ferrara G. Macrolides for chronic asthma. Cochrane Database Syst Rev (2015) 9:Cd002997. doi:10.1002/14651858.CD002997.pub4
72. Yang M, Dong BR, Lu J, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev (2013) 2:Cd007716. doi:10.1002/14651858.CD007716.pub3
73. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax (2013) 68(4):322-9. doi:10.1136/thoraxjnl-2012-202698
74. Kobayashi M, Shimauchi T, Hino R, Tokura Y. Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: its dual inhibitory effects on the ligands and the receptors. Cell Immunol (2004) 228(1):27-33. doi:10.1016/j.cellimm.2004.03.011
75. Ivetic Tkalcevic V, Cužic S, Kramaric MD, Parnham MJ, Erakovic Haber V. Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity. Inflammation (2012) 35(1):192-205. doi:10.1007/s10753-011-9305-9
76. Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther (2014) 143(2):225-45. doi:10.1016/j.pharmthera.2014.03.003
77. Robinson P, Schechter MS, Sly PD, Winfield K, Smith J, Brennan S, et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatr Pulmonol (2012) 47(6):551-7. doi:10.1002/ppul.21613
78. Ito T, Ito N, Hashizume H, Takigawa M. Roxithromycin inhibits chemokine-induced chemotaxis of Th1 and Th2 cells but regulatory T cells. J Dermatol Sci (2009) 54(3):185-91. doi:10.1016/j.jdermsci.2009.01.007
79. Sato Y, Kaneko K, Inoue M. Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production. Prostaglandins Leukot Essent Fatty Acids (2007) 76(3):181-8. doi:10.1016/j.plefa.2006.12.005
80. Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, Zlabinger GJ. Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. Sci Rep (2015) 5:12016. doi:10.1038/srep12016
81. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet (1999) 37(5):385-98. doi:10.2165/00003088-199937050-00003
82. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother (1990) 25(Suppl A):73-82. doi:10.1093/jac/25.suppl_A.73
83. Fraschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, Demartini G. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother (1991) 27(Suppl A):61-5. doi:10.1093/jac/27.suppl_A.61
84. Dette GA. [Tissue penetration of erythromycin (author's transl)]. Infection (1979) 7(3):129-45. doi:10.1007/BF01641314
85. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med (1991) 91(3a):5s-11s. doi:10.1016/0002-9343(91)90394-D